Dr. Chatham is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1707 W Charleston Blvd
Ste 230
Las Vegas, NV 89102Phone+1 702-671-6469
Summary
- Rheumatology section head
Education & Training
- University of Alabama Medical CenterFellowship, Rheumatology, 1986 - 1989
- University of North Carolina HospitalsResidency, Internal Medicine, 1980 - 1983
- Vanderbilt University School of MedicineClass of 1980
- Duke UniversityBSE, Biomedical Engineering, Summa Cum Laude, 1972 - 1976
Certifications & Licensure
- NV State Medical License 2023 - 2025
- AL State Medical License 1986 - 2024
- FL State Medical License 2018 - 2022
- TN State Medical License 1983 - 1992
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Rituximab and Belimumab for Lupus Nephritis Start of enrollment: 2015 Jul 09
- Treatment of Macrophage Activation Syndrome (MAS) With Anakinra Start of enrollment: 2016 May 15
- Early Treatment of Cytokine Storm Syndrome in Covid-19 Start of enrollment: 2020 Aug 01
Publications & Presentations
PubMed
- 1158 citations2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of r...Jasvinder A. Singh, Daniel E. Furst, Aseem Bharat, Jeffrey R. Curtis, Arthur Kavanaugh
Arthritis Care & Research. 2012-05-01 - 108 citationsIFNγ induces epigenetic programming of human T-bethi B cells and promotes TLR7/8 and IL-21 induced differentiation.Esther Zumaquero, Sara L. Stone, Christopher D. Scharer, Scott A. Jenks, Anoma Nellore
Elife. 2019-05-15 - 1073 citationsA phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusRichard Furie, Michelle A. Petri, Omid Zamani, Ricard Cervera, Daniel J. Wallace
Arthritis and Rheumatism. 2011-12-01
Journal Articles
- Cutting Edge: Intracellular IFN-Β and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B CellsW Winn Chatham, John D Mountz, Ignacio Sanz, The Journal of Immunology
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: